JP4596734B2 - スタチン副作用の処置 - Google Patents

スタチン副作用の処置 Download PDF

Info

Publication number
JP4596734B2
JP4596734B2 JP2002545692A JP2002545692A JP4596734B2 JP 4596734 B2 JP4596734 B2 JP 4596734B2 JP 2002545692 A JP2002545692 A JP 2002545692A JP 2002545692 A JP2002545692 A JP 2002545692A JP 4596734 B2 JP4596734 B2 JP 4596734B2
Authority
JP
Japan
Prior art keywords
treatment
composition
uridine
pain
fatigue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002545692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531468A (ja
JP2004531468A5 (enExample
Inventor
アンソニー・ウィリアム・リネイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magral Ltd
Original Assignee
Magral Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magral Ltd filed Critical Magral Ltd
Publication of JP2004531468A publication Critical patent/JP2004531468A/ja
Publication of JP2004531468A5 publication Critical patent/JP2004531468A5/ja
Application granted granted Critical
Publication of JP4596734B2 publication Critical patent/JP4596734B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002545692A 2000-11-29 2001-11-29 スタチン副作用の処置 Expired - Fee Related JP4596734B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR1773A AUPR177300A0 (en) 2000-11-29 2000-11-29 Therapeutic methods
PCT/AU2001/001545 WO2002043721A1 (en) 2000-11-29 2001-11-29 Treatment of statin side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010151665A Division JP2010248230A (ja) 2000-11-29 2010-07-02 スタチン副作用の処置

Publications (3)

Publication Number Publication Date
JP2004531468A JP2004531468A (ja) 2004-10-14
JP2004531468A5 JP2004531468A5 (enExample) 2009-04-02
JP4596734B2 true JP4596734B2 (ja) 2010-12-15

Family

ID=3825810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002545692A Expired - Fee Related JP4596734B2 (ja) 2000-11-29 2001-11-29 スタチン副作用の処置
JP2010151665A Pending JP2010248230A (ja) 2000-11-29 2010-07-02 スタチン副作用の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010151665A Pending JP2010248230A (ja) 2000-11-29 2010-07-02 スタチン副作用の処置

Country Status (10)

Country Link
US (3) US20040063661A1 (enExample)
EP (1) EP1343488B1 (enExample)
JP (2) JP4596734B2 (enExample)
AT (1) ATE369845T1 (enExample)
AU (3) AUPR177300A0 (enExample)
CA (1) CA2429979C (enExample)
DE (1) DE60130023T2 (enExample)
ES (1) ES2292643T3 (enExample)
NZ (1) NZ526069A (enExample)
WO (1) WO2002043721A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR951101A0 (en) * 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
ES2574918T3 (es) * 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
HRP20130459T1 (en) * 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
US20050288379A1 (en) * 2004-06-21 2005-12-29 Xiaoqiang Yan Benzoquinone compounds as anti-cancer agents
JP2008503579A (ja) * 2004-06-21 2008-02-07 ハッチソン メディファーマ エンタープライジズ リミテッド 癌の化学療法
JP4896501B2 (ja) * 2004-11-26 2012-03-14 第一三共株式会社 血中遊離脂肪酸低下作用を有する医薬組成物
WO2006057209A1 (ja) * 2004-11-26 2006-06-01 Sankyo Company, Limited 血中遊離脂肪酸低下作用を有する医薬組成物
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
WO2007061798A2 (en) * 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
US20070286906A1 (en) * 2006-04-28 2007-12-13 Hutchison Medipharma Enterprises Limited Dihydrobenzoquinone compounds
JP2009536215A (ja) * 2006-05-02 2009-10-08 ユニバーシティ オブ マイアミ 局所コエンザイムｑ１０製剤、及び疼痛、疲労、並びに創傷の治療
WO2009089144A1 (en) 2008-01-04 2009-07-16 Isis Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US20110052556A1 (en) 2008-02-29 2011-03-03 Biolab Sanus Farmaceutical Ltda Pharmaceutical composition comprising racetam and carnitine and process for its preparation
JP6058263B2 (ja) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー 癌細胞においてアポトーシスを誘導する方法および使用
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
MX2014001823A (es) * 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
TWI489982B (zh) * 2012-09-18 2015-07-01 Univ China Medical 苯醌類化合物應用於抑制動脈粥狀血管硬化之用途
TWI504390B (zh) * 2012-09-18 2015-10-21 Univ China Medical 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
WO2015003246A1 (en) * 2013-07-09 2015-01-15 Mcmaster University Combination of a statin with an inflammasome inhibitor
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CA3063916A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
WO2018218287A1 (en) * 2017-05-29 2018-12-06 Woodlinda Pty Ltd Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii
US20220088040A1 (en) * 2017-10-13 2022-03-24 Exerkine Corporation Use of System XC-Inhibitor for Treating Statin-Induced Myalgia
KR102060722B1 (ko) * 2017-11-06 2020-02-11 연세대학교 산학협력단 스타틴에 의한 약물유해반응용 동물 모델 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2462312A1 (de) * 1974-03-04 1976-10-14 Nadrol Chemie Pharma Keizer Kg Arzneimittel zur behandlung von migraene-erkrankungen
SU988814A1 (ru) * 1979-11-20 1983-01-15 Филиал Всесоюзного научно-исследовательского химико-фармацевтического института им.Серго Орджоникидзе Соли оротовой кислоты и @ -аминокислот, предупреждающие развитие утомлени при физических нагрузках
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
JPH07504198A (ja) * 1992-02-24 1995-05-11 イースト カロライナ ユニバーシティ デヒドロエピアンドロステロンおよびその類縁体を用いる処置によって発癌を抑制する方法
BE1005939A6 (fr) * 1992-05-14 1994-03-15 Pirmez Thierry Dr Utilisation des sels de l'acide orotique comme tranporteurs preferentiels d'oligo-elements.
WO1993024650A1 (en) * 1992-05-28 1993-12-09 Monash University Therapeutic compositions
AT405477B (de) * 1996-04-03 1999-08-25 Norbert Mag Fuchs Kombinationspräparat
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
IT1317008B1 (it) * 2000-04-04 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare.
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof

Also Published As

Publication number Publication date
AUPR177300A0 (en) 2000-12-21
CA2429979C (en) 2011-11-15
DE60130023T2 (de) 2008-05-08
JP2004531468A (ja) 2004-10-14
EP1343488B1 (en) 2007-08-15
US20100144665A1 (en) 2010-06-10
US20040063661A1 (en) 2004-04-01
ATE369845T1 (de) 2007-09-15
NZ526069A (en) 2006-11-30
EP1343488A1 (en) 2003-09-17
EP1343488A4 (en) 2005-05-04
JP2010248230A (ja) 2010-11-04
US20100323981A1 (en) 2010-12-23
AU2002223302B2 (en) 2006-08-31
ES2292643T3 (es) 2008-03-16
WO2002043721A1 (en) 2002-06-06
HK1059044A1 (en) 2004-06-18
DE60130023D1 (de) 2007-09-27
CA2429979A1 (en) 2002-06-06
AU2330202A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
JP2010248230A (ja) スタチン副作用の処置
AU2002223302A1 (en) Treatment of statin side effects
JP6336914B2 (ja) 脳卒中の治療のためのホルボールエステルの組成物および使用方法
JP2004531468A5 (enExample)
US20070105954A1 (en) Formulation containing a carboxylic acid or an ester thereof
EP0037175B1 (en) Pharmaceutical compositions
IE47777B1 (en) Pharmaceutical and dietary composition comprising gamma-linolenic acids
KR20040004652A (ko) 조효소 ｑ 및 에이코사펜타에노산（ｅｐａ）
JP4986321B2 (ja) 炎症性状態処置のための方法および組成物
NO328797B1 (no) Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt.
US4910224A (en) Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
EP0524796B1 (en) Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS
TWI331920B (en) Unit dosage form for relieving or treating constipation in human patients
KR20230142708A (ko) Pqq 및 이의 유도체의 신규한 응용
IE54556B1 (en) Pharmaceutical composition
JP2024526939A (ja) 酸化的網膜疾患の進行を抑制する方法
JP3816545B2 (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
JP4781629B2 (ja) ウリジン誘導体を用いるスタチンの副作用の処置
HK1059044B (en) Treatment of statin side effects
CN118019529A (zh) 抑制氧化性视网膜疾病进展的方法
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
RU2484841C1 (ru) Способ профилактики атеросклероза, основанный на подавлении атерогенной модификации липопротеидов
JPH05139966A (ja) 月経困難症予防または治療剤と月経困難症予防機能性食品
JP2005247871A (ja) 人工透析患者の副甲状腺機能亢進症治療組成物
JP2000290178A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081209

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100702

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100824

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100921

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131001

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees